| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10620-006-9549-7 |
| P698 | PubMed publication ID | 17211699 |
| P50 | author | Stig B.S. Bengmark | Q54250285 |
| Rami Eliakim | Q110280268 | ||
| P2093 | author name string | Irit Chermesh | |
| Zamir Halpern | |||
| Yehuda Chowers | |||
| Alain Suissa | |||
| Ron Reshef | |||
| Ada Tamir | |||
| Moshe Gelber | |||
| Dalia Katz | |||
| P2860 | cites work | European evidence based consensus on the diagnosis and management of Crohn's disease: special situations | Q22242050 |
| Gastrointestinal effects of prebiotics | Q34135897 | ||
| Predictability of the postoperative course of Crohn's disease | Q34363902 | ||
| Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial | Q34410821 | ||
| Probiotics in inflammatory bowel disease: possible mechanisms of action | Q34423265 | ||
| Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. | Q35594940 | ||
| Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis | Q35596222 | ||
| Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease | Q35760252 | ||
| Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. | Q35760489 | ||
| Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics | Q35787456 | ||
| Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when | Q36036286 | ||
| Preventing postoperative recurrence of Crohn's disease | Q41657791 | ||
| Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial | Q43363077 | ||
| Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. | Q45126890 | ||
| VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis | Q59120549 | ||
| Risk factors for postoperative recurrence of Crohn's disease | Q71825765 | ||
| Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection | Q72281835 | ||
| Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot study | Q81281363 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Crohn's disease | Q1472 |
| P304 | page(s) | 385-389 | |
| P577 | publication date | 2007-01-09 | |
| P1433 | published in | Digestive Diseases and Sciences | Q15716711 |
| P1476 | title | Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease | |
| P478 | volume | 52 |
| Q36699182 | Actual concept of "probiotics": is it more functional to science or business? |
| Q39963407 | Altering and assessing persistence of genetically modified E. coli MG1655 in the large bowel |
| Q37684388 | Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors? |
| Q28817192 | Can probiotics modulate human disease by impacting intestinal barrier function? |
| Q42589189 | Carbohydrate Elimination or Adaptation Diet for Symptoms of Intestinal Discomfort in IBD: Rationales for "Gibsons' Conundrum". |
| Q39265428 | Clinical Evidence for the Microbiome in Inflammatory Diseases |
| Q38162880 | Comparing medical treatments for Crohn's disease. |
| Q37817803 | Consensus guidelines for the management of inflammatory bowel disease |
| Q37667262 | Effects of probiotic supplementation on markers of acute pancreatitis in rats |
| Q55152165 | Efficacy of Lactobacillus plantarum in prevention of inflammatory bowel disease. |
| Q34652744 | Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. |
| Q38180371 | Fiber in the treatment and maintenance of inflammatory bowel disease: a systematic review of randomized controlled trials |
| Q44527892 | Immunological properties of inulin-type fructans |
| Q37969593 | Indications for the use of probiotics in gastrointestinal diseases |
| Q36555442 | Integrative medicine and human health - the role of pre-, pro- and synbiotics |
| Q90075252 | Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis |
| Q24240542 | Interventions for prevention of post-operative recurrence of Crohn's disease |
| Q35245299 | Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease |
| Q39167564 | Lactobacillus plantarum and Its Probiotic and Food Potentialities |
| Q37120949 | Management of postoperative Crohn's disease. |
| Q37324642 | Managing medical complications and recurrence after surgery for Crohn's disease |
| Q28072437 | Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate |
| Q35646449 | Nutraceutical Supplements for Inflammatory Bowel Disease |
| Q41060588 | Nutritional management of adults with inflammatory bowel disease: practical lessons from the available evidence |
| Q90259227 | Pectin Oligosaccharides Ameliorate Colon Cancer by Regulating Oxidative Stress- and Inflammation-Activated Signaling Pathways |
| Q89706649 | Pharmacological Prevention of Postoperative Recurrence in Crohn's Disease |
| Q37276985 | Postoperative Crohn's disease recurrence: a practical approach |
| Q37914790 | Postoperative recurrent luminal Crohn's disease: a systematic review |
| Q37305785 | Postoperative therapy for Crohn's disease |
| Q34141652 | Prebiotic effects: metabolic and health benefits |
| Q37285115 | Prebiotics in chronic intestinal inflammation |
| Q34836049 | Prebiotics, immune function, infection and inflammation: a review of the evidence. |
| Q34789021 | Predicting, treating and preventing postoperative recurrence of Crohn's disease: the state of the field |
| Q38153302 | Preventing postoperative recurrence in Crohn's disease: what does the future hold? |
| Q55533457 | Prevention and Treatment Options for Postoperative Crohn’s Disease: A Clinical Dilemma. |
| Q37806150 | Prevention and treatment of postoperative Crohn's disease recurrence: an update for a new decade |
| Q38191578 | Prevention of post-operative recurrence of Crohn's disease. |
| Q37991447 | Prevention of postoperative recurrence of Crohn's disease |
| Q38125810 | Probiotics and clinical effects: is the number what counts? |
| Q38009716 | Probiotics for the treatment of inflammatory bowel disease |
| Q27002496 | Probiotics in inflammatory bowel diseases and associated conditions |
| Q37492720 | Probiotics in pediatric inflammatory bowel diseases |
| Q38970657 | Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. |
| Q37345932 | Rationale for probiotic treatment strategies in inflammatory bowel disease |
| Q98892417 | Regulation of the intestinal microbiota: An emerging therapeutic strategy for inflammatory bowel disease |
| Q35171537 | Risk of postoperative recurrence and postoperative management of Crohn's disease |
| Q38104578 | State-of-the-art medical prevention of postoperative recurrence of Crohn's disease |
| Q28254207 | Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease |
| Q33939802 | Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era |
| Q37991910 | Targeting the intestinal microbiota in the pediatric population: a clinical perspective |
| Q42948622 | The antimicrobial action of low-molar-mass chitosan, chitosan derivatives and chitooligosaccharides on bifidobacteria. |
| Q38051707 | The evolving management of postoperative Crohn's disease |
| Q27001546 | The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials |
| Q34152778 | The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations |
| Q38321531 | Therapeutic Manipulation of the Microbiome in IBD: Current Results and Future Approaches |
| Q37767505 | Therapeutical use of probiotic formulations in clinical practice. |
| Q37729039 | Update on the role of probiotics in the therapy of pediatric inflammatory bowel disease |
| Q37823328 | Use of probiotics in gastrointestinal disorders: what to recommend? |
| Q35770445 | What colorectal surgeons should know about probiotics: a review |
Search more.